In this interview, recorded at the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, gives us an overview of the benefits of a combined carfilzomib and dexamethasone (Kd) therapy for treating relapsed multiple myeloma (MM). Dr Popat discusses the results from the Phase III ENDEAVOUR trial (NCT01568866), which compared the efficacy of bortezomib and dexamethasone (Vd) therapy with Kd treatment. Kd therapy was shown to double PFS and increase overall survival when compared to standard Vd treatment; however, the use of these drugs is still restricted to certain patient groups in the UK.
ENDEAVOUR: carfilzomib/dexamethasone therapy for relapsed MM
